Eli Lilly just released impressive study results for retatrutide, an investigational weight loss drug that targets three ...
Nancy E. Davidson, MD, executive vice president and chief academic officer at Fred Hutch Cancer Center, is the recipient of ...
Morning Overview on MSN
A new genomic test could spare two-thirds of high-risk breast cancer patients from chemotherapy entirely, per ASCO 2026 results
Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, ...
A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar ...
A second-line triplet regimen involving the novel intravenous drug gedatolisib significantly reduced the risk of progression ...
Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY ...
Morning Overview on MSN
Ruptosis — the explosive cell death researchers just named in flatworms — kills surrounding cells faster than any previously known cell-death pathway
A newly identified cell type in planarian flatworms can detonate itself and destroy neighboring cells in less than two ...
AstraZeneca will discontinue the Zoladex 3.6mg implant in Australia from November 2026, affecting people with breast cancer ...
GIP drugs such as tirzepatide (Mounjaro, Zepbound) are transforming metabolic health. Learn how they work, their uses, and ...
Israeli-led researchers have identified a previously underappreciated mechanism that may explain why many prostate cancers ...
At ASCO, researchers shared that in the persevERA trial, giredestrant didn't improve outcomes for first-line advanced breast ...
You've probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results